US 12,030,861 B1
L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof
Raphaël Darteil, Lyons (FR); Jacky Vonderscher, Senouillac (FR); Diane Sampson, Valbonne (FR); Nicolas Philippon, L'Haÿ-les-Roses (FR); Joël Vacus, Saint Maurice-Montcouronne (FR); Julien Leroudier, Buchelay (FR); Sandra Werner, Ostwald (FR); and Françoise Richard-Tiberghien, Geispolsheim (FR)
Assigned to ENYO PHARMA, Lyons (FR)
Filed by ENYO PHARMA, Lyons (FR)
Filed on Jul. 13, 2023, as Appl. No. 18/351,587.
Int. Cl. C07D 307/85 (2006.01); A61K 45/06 (2006.01)
CPC C07D 307/85 (2013.01) [A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 48 Claims
OG exemplary drawing
 
1. An L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid in a crystalline form, wherein the X-ray diffraction pattern of the crystalline form comprises peaks at diffraction angles 2-Theta (2θ) of: 7.6°±0.2°, 10.1°±0.2°, 12.6°±0.2°, 15.1°±0.2°, 17.6°±0.2°, and 20.1°±0.2°, and wherein the X-ray diffraction pattern is obtained with a Cu Kα anode.